Skip to main content
. 2021 Dec 9;9:783385. doi: 10.3389/fcell.2021.783385

FIGURE 1.

FIGURE 1

DUXAP8 is highly expressed in sorafenib-treated patient-derived xenograft (PDX) hepatocellular carcinoma model, and its upregulation predicts poor prognosis of HCC. (A) Experimental procedure of the sorafenib-treated PDX HCC model. (B) The heat map indicates the differential expression of lncRNAs in sorafenib-treated and control P4-PDX mice. (C) Comparison of DUXAP8 expression in liver cancer tissues of 15 HCC patients with paired pericarcinomatous normal tissues. (D) Comparison of DUXAP8 expression in HCC tissues of 85 HCC patients with paired pericarcinomatous normal tissues. (E) Relationship between DUXAP8 expression in liver cancer tissues of 85 patients and the presence of distant metastasis. (F) Kaplan-Meier analysis of the correlation between DUXAP8 expression levels and HCC prognosis in 79 patients. (G) Comparison of DUXAP8 expression in HCC cell lines and THLE-3 cells. (H) RT–qPCR assay of the distribution of DUXAP8 in the nucleus and cytoplasm of HCC cells. Data are expressed as mean, *p < 0.05, **p < 0.01.